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The production of ozone-depleting chlorofluorocarbons (CFCs) was discontinued on 1 January 1996 for all uses 
deemed non-essential under the Montreal Protocol. However, the use of CFCs as propellants in pressurized 
metered ose inhalers (pMDIs) was classed as essential, providing an exemption from the agreement. Following 
extensive research, the hydrofluoroalkanes (HFA) 134a and 227 were identified as the only suitable replacements 
for CFC propellants in pMDIs. 
The drug delivery of pMDIs formulated with HFA 134a as a propellant and containing either salbutamol (100 #g 
per actuation) or fluticasone propionate (125 and 250/ag per actuation) have been assessed for dose uniformity and 
particle size distribution. 
All of the HFA 134a pMDIs delivered oses throughout the life of the canisters that were reproducible and 
within specified regulatory requirements. Each of the products provided an emitted ose which was within +25% 
of the mean value indicating accurate and consistent dosing (93, 112 and 221 ltg per metered dose for the 
salbutamol 100/2g and fluticasone propionate 125 and 250/~g HFA 134a pMDIs, respectively). These findings were 
unaffected by changing the storage orientation of the pMDI or by using the device in a manner designed to simulate 
typical patient use. The particle size distributions of HFA 134a pMDI doses did not differ significantly from those 
of the corresponding CFC pMDIs. As a result of the similar pharmaceutical performance, it is unnecessary to 
change the label claim dose of active drug when making the transition from a CFC to an HFA 134a pMDI for 
salbutamol (Ventolin TM) and fluticasone propionate (FlixotideXM). A seamless transition to non-CFC pMDIs will 
help to maintain the confidence of patients and healthcare professionals in asthma therapy. 
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Protocol; CFC transition. 
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Introduction 
Under the Montreal Protocol, the production of ozone- 
depleting chloroftuorocarbons (CFC) was discontinued on 
1 January 1996 for all uses deemed non-essential (1). 
However, the pharmaceutical use of CFC propellants in 
pressurized metered ose inhalers (pMDIs) was given an 
exemption, thereby providing a time period to develop 
alternative propellants. Subsequent research led to the 
development of hydrofluoroalkanes (HFA), and 1,1,1,2 
tetrafluoroethane (HFA 134a) was chosen as the replace- 
ment propellant for pMDIs containing salbutamol (Vento- 
lin TM) and fluticasone propionate (FlixotideTM). HFA 134a 
does not deplete the ozone layer, and animal studies have 
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shown that it has an exceptionally good toxicity profile, 
without geno- or fetotoxicity, and does not affect peri- or 
postnatal development (2,3). 
When evaluating new HFA 134a pMDIs, it is important 
to compare the dose delivery and particle size distribution 
with that of existing CFC pMDIs. Considerable formula- 
tion changes were necessary when switching to HFA 134a. 
The incorporation of cosolvents uch as ethanol proved 
necessary if those surfactants routinely used in the CFC 
pMDI were to be used, as the traditional surfactants are not 
sufficiently soluble in HFA 134a (4). Ethanol has been used 
as a cosolvent in either suspension or solution formulations. 
However, in the cases of VentolinT M and Flixotide TM, an 
alternative approach was adopted in which suspension 
formulations were developed in the absence of excipients 
other than the propellant. 
In conjuction with these formulation changes, it was 
essential to maintain the particle size distribution close to 
that of the CFC pMDIs. Establishing the performance of 
new products in these terms is essential to demonstrate hat 
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new non-CFC pMDIs meet the regulatory requirements 
~laid down by the Committee for Propriety Medicirlal 
Products (CPMP) and other regulatory agencies around 
the world (5). In recognition of the need to validate the 
performance of the HFA pMDI products with the 
appropriate spacer devices, particle size data were gener- 
ated for both salbutamol (Ventolin TM) and fluticasone 
propionate (Flixotide TM) with the Volumatic TM and 
Babyhaler TM spacer devices. 
The present in vitro study was conducted to establish the 
accuracy and consistency of dosing throughout the life of 
the canister, and the particle size distribution of active 
ingredient (salbutamol or fluticasone propinate) released 
from a pMDI using HFA 134a as the propellant. 
Methods 
DOSE UNIFORMITY 
HFA 134a pMDIs containing salbutamol 100pg and 
flucticasone propionate 125 and 250#g per actuation were 
tested to determine dosing reproducibility. This was 
achieved using a variety of test protocols designed to 
evaluate single actuation reproducibility, content unifor- 
mity and simulated patient use. 
The test for single actuation reproducibility measures the 
consistency of drug content in single actuations discharged 
from the inhaler during a typical dosing regimen. Nine 
pMDIs for each of the three formulations were primed and 
two single actuations from each inhaler were collected 
separately. Each pMDI was shaken prior to priming and 
collection of each actuation. The inhalers were then stored 
such that three inhalers were placed in each of the valve-up, 
valve-down and valve-horizontal orientations. Throughout 
the following 3.5 days, the contents of two consecutive 
actuations were collected separately once in the morning 
and evening for the flucticasone propionate pMDI and the 
contents of two actuations were collected separately 
morning and evening for the salbutamol pMDI. Each 
inhaler was stored in the defined orientation between 
collections. 
The test for content uniformity aims to assess the 
accuracy and uniformity of dosing. During the test, the 
delivered ose collected at the beginning of the products's 
use and again after delivery of the label claim number of 
actuations was measured for 10 pMDIs for each of the 
three formulations. For fluticasone propionate, the deliv- 
ered dose comprised two actuations (namely actuations 1
and 2 and actuations 119 and 120), whereas for salbutamol, 
the delivered dose corresponded to actuation 1 at the 
beginning of use and actuation 200 at the end of use. 
The simulated use test was designed to reflect patient use 
of the product. Two actuations were released four times 
daily and twice daily from the salbutamol and fluticasone 
propionate pMDIs, respectively, until the last of the label 
claim actuations had been released (i.e. 200 actuations for 
salbutamol and 120 actuations for fluticasone propionate). 
The mean content of drug per actuation was determined at 
multiple points between the first and final actuation. Five 
pMDIs were tested for each of the three formulations. 
For all dose delivery analyses, the actuated oses were 
collected from the pMDI after shaking into a 500ml 
separatory funnel fitted with a cotton wool plug compacted 
into its base, through which air was drawn at 20 I rain - I .  
After 1 min the airflow was disconnected and the funnel 
was rinsed several times with methanol. The amount of 
active ingredient in each actuation was determined using 
high-performance liquid chromatography (HPLC). 
PARTICLE SIZE DISTRIBUTION 
An Andersen cascade impactor (Andersen Samplers Inc, 
Atlanta, Georgia, U.S.A.) fitted with a small volume metal 
induction port (throat) was used to determine the particle 
size distribution of the active constituent (salbutamol or 
fluticasone propionate) in an actuated ose released from a 
HFA 134a or CFC pMDI. 
The cascade impactor contains eight aluminium stages 
held together by spring clamps and airtight seals. The plates 
of the cascade impactor were not coated with silicone. The 
aerosol spray is introduced through an induction port 
(throat), and the aerosol particles are drawn through the 
impactor by a stream of air (28 1 min- t). Each aluminium 
stage contains a defined number of accurately drilled holes, 
which decrease in size from stage 0 to stage 7. Thus, 
particles of a defined size range are collected by each stage 
(Table 1). 
The primed inhaler was shaken and the contents of a 
single actuation were released into the Andersen cascade 
impactor. This process was repeated until five actuations 
for salbutamol and 10 actuations for fluticasone propionate 
had been discharged into the impactor. Each stage of the 
impactor, including the collection plates and filter, was then 
washed separately with methanol and the washings 
collected. The amount of active ingredient on each stage 
was determined by HPLC and expressed as the amount of 
active constituent per metered ose. 
TABLE 1. The relationship between particle size and particle 
penetration into the airways and stages of the Andersen 
cascade impactor (operated at 28 I min- I )  
Stage Particle size Deposition in respiratory tract 
(pm) 
0 9.00-10.00 
1 5-80-9"00 
2 4"70-5"80 
3 3"30-4"70 
4 2.10-3.30 
5 1.10-2" 10 
6 0"65-1-10 
7 0-43-0-65 
Filter < 0"43 
Pharynx 
Trachea and primary bronchi 
Secondary bronchi 
Terminal bronchi 
Alveoli 
Alveoli 
For each pMDI, particle size distributions were 
assessed with the standard actuator only, then with 
the Volumatic TM spacer fitted. In addition, the 
salbutamol pMDI was tested with the Babyhaler TM spacer 
device. 
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Results 
As for all inhaler device testing, a proportion of the metered 
dose delivered from the formulation adheres to the surfaces 
in contact with the product. In the case of pMDIs, a dose is 
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FIG. I. Drug content delivered uring single actuation reproducibility testing for (a) fluticasone propionate and (b) 
salbutamol hydrofluoroalkane (HFA) 134a pressurized metered ose inhalers (pMDIs) in three storage orientations. 
TABLE 2. Content uniformity for the ex-actuator content of salbutamol 100/~g and fluticasone propionate 125 #g and 250 pg 
hydrofluoroalkane (HFA) 134a pressurized metered ose inhalers (pMDIs) 
Salbutamol (pg per 
metered ose) 
Fluticasone propionate (yg per metered ose) 
Ex-actuator target 90ltg l l0pg 220yg 
N 10 10 10 
pMDI number 1st 200th 1st and 2nd 119th and 1st and 2nd l l9th and 
actuation actuation actuation 120th actuation 120th 
(mean) actuation (mean) actuation 
(mean) (mean) 
1 84 102 118 113 217 233 
2 86 99 108 109 212 233 
3 93 97 101 110 212 225 
4 91 87 126 110 218 224 
5 83 104 115 111 223 212 
6 87 97 105 112 214 226 
7 89 96 106 113 217 223 
8 91 102 123 112 211 232 
9 78 - ."  105 120 102 211 227 
10 83 86 111 111 216 225 
Mean" 93 112 221 
± 10%oflabel claim 81-99 99-121 198-242 
±25%of  mean t 70-116 84--140 166-276 
±35%of  mean t 60-126 73-151 144-298 
*Overall mean of 20 results. 
tAs defined by CPMP guidelines for content uniformity. 
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Ftc. 2. Drug content delivered uring simulated use 
testing for salbutamol and fluticasone propionate 
hydrofluoroalkane (HFA) 134a pressurized metered ose 
inhalers (pMDIs). The five lines on each graph represent 
the five MDIs used for each formulation 
delivered by the valve (the ex-valve dose) and an amount of 
the dose is retained on the actuator. The dose reaching the 
patient is termed the ex-actuator dose. In practice, 100/~g of 
salbutamol released from the valve equates to 90ltg 
released from the actuator and 125 and 2501tg of 
flucticasone propionate released from the valve equates to 
110 and 220/~g released from the actuator, respectively. 
SINGLE ACTUATION REPRODUCIBILITY 
The data for all three HFA 134a products showed 
consistent performance in all three orientations (Fig. 1). 
This demonstrates the durability of the performance of the 
HFA 134a pMDI under storage conditions likely to be 
encountered uring patient use. All products tested 
remained close to the target value for the active ingredient 
per actuation throughout the test period. 
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FIG. 3. Particle size distribution of salbutamol and ' 
fluticasone propionate hydrofluoroalkane (HFA) 134a 
and chlorofluorocarbon (CFC) metered ose inhalers. 
Particle size distribution was measured using an Andersen 
cascade impactor. 
CONTENT UNIFORMITY 
Data on the content per actuation for 10 salbutamol and 10 
fluticasone propionate HFA 134a pMDIs are presented in 
Table 2. Each of the products provided individual contents 
per actuation which were within +25% of the mean value, 
indicating accurate and consistent dosing. For each 
product, the overall mean content per actuation was within 
+ 10% of the target ex-actuator value. This complies with 
the first tier of testing for the CPMP specification (5). 
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FIG. 4. Particle size distribution profiles for 
hydrofluoroalkane (HFA) 134a pressurized metered ose 
inhalers (pMDIs) with or without fitted spacer devices, 
containing (a) salhutamol 100#g, (b) fluticasone 
propionate 125 #g and (c) fluticasone propionate 
250/ag. 
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SIMULATED USE 
For all three products (salbutamol 100gg and fluticasone 
propionate 125 and 250#g HFA 134a pMDIs), the 
delivered doses closely approximated to the target values 
throughout the label claim number of actuations (Fig. 2). 
This simulation of patient use provides valuable informa- 
tion about the consistency of the product performance. The 
data for all five canisters tested for each product were 
similar, indicating a high degree of inter-canister consis- 
tency over the label claim contents of the inhaler. 
PARTICLE SIZE DISTRIBUTION 
The particle size distributions for the corresponding HFA 
134a and CFC salbutamol and fluticasone propionate 
pMDIs were similar (Fig. 3). Figure 4 demonstrates that 
use of the salbutamol HFA 134a pMDI in conjuction with 
the Volumatic TM and Babyhaler TM spacer devices had:no 
significant effect on the particle size distribution profiles of 
salbutamol other than a significant reduction in throat 
deposition. The Volumatic TM spacer had a similar effect on 
the fluticasone propionate pMDIs. The mass median 
aerodynamic diameter (MMAD) for salbutamol with the 
HFA 134a pMDI was 2.4pm, and 2.2ym with the CFC 
pMDI. In the case of fluticasone propionate, MMAD 
values differed according to dose, but were comparable for 
the HFA 134a and CFC formulations (125 #g dose: 2.4/an 
and 2.8/~m, respectively; 250 yg dose: 2-6/~m and 3.2/1m) 
The active drug deposition in the throat and spacer after 
dose actuation with or without spacer devices, together 
with the fine particle mass, are presented in Table 3. 
DISCUSSION 
These data show that it has been possible to formulate non- 
CFC pMDIs for salbutamol and fluticasone propionate 
with a similar h) vitro pharmaceutical performance to the 
CFC pMDIs. This development was particularly challen- 
ging because the physicochemical properties of HFA 134a 
necessitated modification of the formulation and the 
primary packaging components for both the salbutamol 
and fluticasone propionate pMDIs in order to achieve an 
equivalent pharmaceutical profile. 
The simulated use results of this study demonstrate hat 
the amount of salbutamol and fluticasone propionate 
released per metered ose of the HFA 134a pMDIs was 
consistent throughout the label claim number of actuations 
when the product was used according to a typical patient 
dosing regimen. 
Due to their physicochemical properties, suspension 
aerosols can be sensitive to the effects of' separation of the 
suspended particles within the valve on standing due to 
either creaming or sedimentation, and this can affect the 
dosing characteristics of the product (6). Careful evaluation 
of all suspension formulations is therefore required. 
Measurement of the single actuation content reproduci- 
bility demonstrated that the amount of active ingredient 
delivered in each actuation was unaffected by the storage 
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orientation of the inhaler over periods typical of those 
elapsing between patient use. The data showed that the 
content per actuation of HFA 134a pMDIs was consis- 
tently close to the target dose delivery values. 
The particle size distribution of active ingredient from the 
HFA 134a and CFC pMDls was determined using the 
Andersen cascade impactor. The size distribution of fine 
particles in the discharged aerosol can be expected to relate 
to the degree of drug penetration i to the respiratory tract. 
Indeed, there is a. correlation between particle penetration 
through the stages of the Andersen cascade impactor and fll 
vivo penetration of particles into the airways (7-9). Thus, 
the fact that the HFA 134a pMDI particle size distribution 
results are similar to those from the corresponding CFC 
pMDls suggests that the total lung deposition character- 
istics of these deviqes are similar. 
The optimal particle size necessary for the bronchodi- 
lator salbutamol to achieve a demonstrable increase in lung 
function is 31Lm (10). In this study the mass median 
aerodynamic diameters of the salbutamol particles were 2.1 
and 3.3pm for the HFA 134a and CFC pMDIs, 
respectively. The similarity of both the delivered ose and 
fine particle fractions of salbutamol from HFA 134a and 
CFC pMDIs underpins the clinical equivalence of these 
devices. This clinical equivalence has been indicated by 
single-dose pharmacological and multiple-dose clinical 
studies (I 1-13). 
A relationship between the site of pulmonary deposition 
of inhaled corticosteroids and their anti-inflammatory effect 
has not been demonstrated. Howex~er, a recent reformula- 
tion of the beclomethasone dipropionate inhaler 
(QVAR TM) using ethanol resulted in an increase in the 
proportion of fine particles less than 1.1 l~m. This 
TABLE 3. Cascade impactor data for hydrofluoroalkane (HFA) 
without spacer devices 
necessitated a two-fold reduction in dosage with the new 
formulation compared with the CFC pMDI, under certain 
circumstances (14). The lung deposition data for QVAR TM, 
in comparison, suggest a six-fold increase in the quantity of 
drug reaclaing the lung with QVAR TM (14). Thus there is a 
discrepancy between lung deposition and the resultant 
clinical efficacy, and the relationship between lung deposi- 
tion and clinical efficacy and safety remains poorly under- 
stood. 
The characteristics of the aerosol spray can be influenced 
by the formulation and packaging components. It has 
been reported that the plume temperature for salbutamol 
HFA products (Proventil TM HFA containing ethanol; 
Sultanol N TM or Ventolin TM CFC-free excipient-free) 
is warmer than that of some comparator CFC products 
(15). The excipient-free formulation in this study 
maintained the same impact force as the CFC 
formulation. This provides reassurance that patients will 
experience a similar sensation from the aerosol spray when 
taking a dose (15). 
The addition of a spacer device had no effect on the 
particle size distribution of the HFA 134a pMDls, 
although, as with the CFC pMDIs, there was a slight 
increase in fine particle mass. These data indicate that the 
new pMDls can be used successfully in conjuction 
with spacer devices in the same way as currently available 
CFC pMDIs. The slight increase in fine particle mass, 
regardless of propellant, is likely to be due to the 
deceleration of the aerosol through the spacer and increased 
droplet evaporation within the spacer. However, these 
differences are unlikely to be of clinical significance 
given the inter-patient variability seen with inhaled drug 
delivery. 
134a and chlorofluorocarbon (CFC) pMDls used with or 
Ex-actuator 
dose (/ag) 
Throat Spacer Fine particle mass 
deposition deposition (sum of stages 3-5*; l~g) 
(~'g) (~g) 
Salbutamol 100pg (HFA 134a propellant) 
Standard actuator 82 
Volumatic TM spacer 90 
Babyhaler TM spacer 93 
Fluticasone propionate 125/~g (HFA 134a propellant) 
Standard actuator 101 
Volumatic TM spacer I 13 
Fluticasone propionate 125 fig (CFC propellant) 
Standard actuator 109 
Volumatic TM spacer 109 
Fluticasone propionate 250/~g (HFA 134a propellant) 
Standard actuator 206 
Volumatic TM spacer 234 
Fluticasone propionate 250 pg (CFC propellant) 
Standard actuator 223 
Volumatic TM spacer 231 
39 - -  34 
1.3 37 43 
• 0.7 54 33 
35 - -  54 
1.1 28 72 
45 - -  56 
0.4 34 67 
79 - -  102 
1.8 102 111 
98 - -  106 
1.2 82 131 
*Stages 2-6 for the salbutamol pMDI 
In conclusion, the results of this study suggest hat the 
replacement of CFC propellants with non-ozone depleting 
HFA 134a in pMDIs has now become feasible, without 
affecting the pharmaceutical characteristics of these devices. 
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